169 related articles for article (PubMed ID: 11907423)
1. De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination.
Langer RM; Van Buren CT; Katz SM; Kahan BD
Transplantation; 2002 Mar; 73(5):756-60. PubMed ID: 11907423
[TBL] [Abstract][Full Text] [Related]
2. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
[TBL] [Abstract][Full Text] [Related]
3. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
[TBL] [Abstract][Full Text] [Related]
4. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
Pliszczynski J; Kahan BD
Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
[TBL] [Abstract][Full Text] [Related]
5. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
Zhu L; Ding T; Wang XX; Lin ZB; Chen G
Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
[TBL] [Abstract][Full Text] [Related]
9. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management.
Hong JC; Kahan BD
Transplantation; 2000 May; 69(10):2085-90. PubMed ID: 10852601
[TBL] [Abstract][Full Text] [Related]
11. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
12. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy?
Franz M; Regele H; Schmaldienst S; Stummvoll HK; Hörl WH; Pohanka E
Transplantation; 1998 Nov; 66(9):1258-62. PubMed ID: 9825827
[TBL] [Abstract][Full Text] [Related]
13. Addition of induction therapy offsets the hazard of marked calcineurin minimization among renal transplant recipients treated with sirolimus.
Kahan BD; Benavides C; Schoenberg L; Podbielski J; Green C
Clin Nephrol; 2010 May; 73(5):344-53. PubMed ID: 20420794
[TBL] [Abstract][Full Text] [Related]
14. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
15. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
Baboolal K
Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
[TBL] [Abstract][Full Text] [Related]
16. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
[TBL] [Abstract][Full Text] [Related]
17. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
18. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
19. Can we eliminate both calcineurin inhibitors and steroids?
Lebranchu Y
Transplant Proc; 2010 Nov; 42(9 Suppl):S25-8. PubMed ID: 21095446
[TBL] [Abstract][Full Text] [Related]
20. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function.
Hong JC; Kahan BD
Transplantation; 2001 May; 71(9):1320-8. PubMed ID: 11397971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
